Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kailera Therapeutics

Request full access

A clinical-stage biopharma company advancing a diverse therapeutic pipeline aimed at delivering innovative treatments for obesity and related conditions

Waltham, United StatesFounded 2024Biotech & Life Sciences

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on the rapidly growing market for obesity and related metabolic conditions. The company launched in October 2024 with a substantial $400 million Series A financing, co-led by prominent investors Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with Lyra Capital also participating. This significant initial funding allows Kailera to bypass early research stages and advance a portfolio of clinical-stage assets. The company's business model centers on acquiring and developing promising drug candidates. In May 2024, Kailera secured exclusive rights to develop and commercialize a portfolio of four metabolic disease assets outside of Greater China from Jiangsu Hengrui Pharmaceuticals.

The leadership team is composed of seasoned biotech executives. CEO Ron Renaud has a notable history of leading companies to successful acquisitions, including Cerevel Therapeutics (acquired by AbbVie), Translate Bio (acquired by Sanofi), and Idenix Pharmaceuticals (acquired by Merck & Co.). The board is chaired by John F. Milligan, the former President and CEO of Gilead Sciences, who was instrumental in its growth into a global biopharmaceutical leader.

Kailera's product pipeline is diverse, featuring both injectable and oral therapies targeting chronic weight management. Its most advanced program is KAI-9531, an injectable dual agonist targeting GLP-1 and GIP receptors. This candidate has already produced compelling results in Phase 2 trials for obesity and type 2 diabetes conducted in China. The pipeline also includes KAI-7535, an oral small molecule GLP-1 receptor agonist; an oral tablet formulation of KAI-9531; and KAI-4729, an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors. This multi-faceted approach, with various mechanisms and delivery routes, is designed to address complex patient needs in a market currently dominated by major pharmaceutical players.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2026

Kailera Therapeutics in the Waltham ecosystem

Live from Dealroom

The Kailera Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

24 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A14 investors entered at this stage

Series B and later10 investors entered at this stage

Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Kailera Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.